OPEN END TURBO BULL OPTIONSSCHEIN - VERTEX PHARMACEUTICALS | Market Closed - Deutsche Boerse AG 13:33:18 2024-06-14 EDT | ||
| 20.87 EUR | +2.00% |
|
| Current month | +17.51% | ||
| 1 month | +35.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-06-14 | 20.87 | +2.00% |
| 24-06-13 | 20.46 | +1.69% |
| 24-06-12 | 20.12 | -2.38% |
| 24-06-11 | 20.61 | -0.24% |
| 24-06-10 | 20.66 | -0.86% |
Delayed Quote Deutsche Boerse AG
Last update June 14, 2024 at 01:33 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC41QD |
| ISIN | DE000HC41QD0 |
| Date issued | 2023-02-10 |
| Strike | 260.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 6.17 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 20.95 € |
|---|---|
| Lowest since issue | 5.3 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
